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Paroxysmal dyskinesias (PxD) refer to a rare group of clinically and genetically 
heterogeneous disorders presenting with recurrent attacks of abnormal movements, 
typically dystonia, chorea or a combination thereof, without loss of consciousness. 
Classically, PxD have been categorized according to their triggers and duration of the 
attacks, but increasing evidence suggests that there is a certain degree of clinical and 
genetic overlap and challenges the concept that one phenotype is attributable to one 
single aetiology. Here we review the increasing spectrum of genetic conditions, as well 
as of other non-genetic disorders, that might present with PxD, provide criteria for 
case-definition and propose a diagnostic work-up to reach a definitive diagnosis, upon 















Paroxysmal dyskinesias (PxD) are a group of heterogeneous syndromes that 
characteristically manifest with recurrent attacks of abnormal movements, typically 
dystonia, chorea or a combination thereof, without loss of consciousness1.  
Considering the etymology and literal meaning of the words “paroxysmal” and 
“dyskinesia”, one would realize that neither term is specific enough to unequivocally 
identify the entities that are classically referred to as PxD. The term “paroxysmal”, 
(from Greek paroxusmós - irritation, the severe fit of a disease) refers to sudden attack, 
recurrence, or intensification of a disease2. According to this definition, even waxing-
and-waning conditions like tic syndromes or movement disorders that appear or worsen 
on action (action-myoclonus or action-tremor for instance) would fit into this category. 
The term dyskinesia (from Greek, dys + kinesis, altered movement) is also used in the 
medical literature with different meanings. Some medical dictionaries propose that it 
should be used to indicate an impairment of the ability to execute voluntary 
movements3, whereas others emphasize the hyper-kinetic nature of the disorder and 
suggest that dyskinesias are involuntary jerky or slow writhing movements, often of a 
fixed pattern, including tics, myoclonus, chorea and dystonia4.  
It appears clear that such definitions are too broad and do not match with the meaning 
that movement disorder experts give to the term “paroxysmal dyskinesias”. This calls 
for the need for a clear definition of what should be intended as PxD, to avoid further 
ambiguity in the literature.  
Moreover, increasing knowledge regarding the possible aetiologies underlying the PxD 
has challenged the concept they could represent distinct disease entities (i.e., that one 
phenotype could be only attributable to one single aetiology)5–7. Hence, following a 
brief overview of the historical aspects and the classification of PxD based on triggers 
(see below), a further in-depth section will be structured according to the different 
aetiologies that produce PxD. This section will cover novel genetic disorders that might 
encompass in their phenotype paroxysmal dystonia and/or chorea, but escape the 
current classification of PxD.  
A final section is meant to provide a diagnostic strategy to deal with PxD. This 
framework emphasizes that these diagnostic labels represent clinical syndromes (and 
not disease entities), provides criteria for case-definition, and endorses the approach 
recently used for dystonia in general8 (i.e., isolated versus combined PxD, thereby 
discarding the former criterion requiring normal neurological examination between the 
attacks). On the basis of different clinical features including, but not limited to, triggers, 
appropriate investigations are suggested to reach a definite diagnosis, upon which 
treatment is heavily dependent. It is not in the aims of the current paper to review the 
pathophysiological mechanisms underpinning this group of disorders and the interested 
readers are referred elsewhere9. The search strategy is detailed in box 1. 
 
BOX 1 
Search strategy and selection criteria 
References for this Review were identified by searches of PubMed, EMBASE and 
Google Scholar, between 1940 and January 2018, and references from both 
relevant articles and book chapters. The search terms “paroxysmal dyskinesias”, 
“paroxysmal dystonia”, “PRRT2”, “MR-1”, “SCL2A1”, “GLUT1”, “KNCMA1”, 
“ADCY5”, “ATP1A3”, “PKD”, “PNKD”, and “PED” were used. There were no 
language restrictions. The final reference list was generated on the basis of 
relevance to the topics covered in this Review. 
  
2. Historical definition and classification of paroxysmal dyskinesias 
Between 1940 and 1977, three main forms of episodic movement disorders were 
recognized10–12 and classified based on the duration of attacks12. Following this earlier 
classification12, a subsequent proposal by Demirkiran and Jankovic discarded the 
duration of attacks as informative and focused on the difference between triggers13. 
They recognized three subtypes, encompassing paroxysmal kinesigenic (PKD), non-
kinesigenic (PNKD), and exercise-induced (PED) dyskinesias13. The term dyskinesia 
was privileged over others previously adopted because the specific phenomenology of 
the attacks (i.e., dystonia vs chorea) could only be presumed based on patients’ 
description. A fourth subtype was also proposed [i.e. paroxysmal hypnogenic 
dyskinesias (PHD) characterized by attacks occurring during sleep without identifiable 
trigger]13, but this entity has been subsequently suggested to be a form of autosomal 
dominant nocturnal frontal lobe epilepsy (ADNFLE) in most cases14.  
Each of these forms could be further stratified into primary and secondary disorders13. 
However, the term “primary” is increasingly dismissed as it carries the implication that 
there is absence of detectable abnormalities15, whereas most primary PxD are in fact 
found to be secondary to a genetic defect. Moreover, it was suggested that patients with 
secondary PxD have inter-ictal signs reflecting the underlying disorder13, as opposed to 
cases with primary PxD. However, as anticipated above and discussed in detail below, 
many patients with “primary” genetic forms of PxD do have inter-ictal findings on 
examination. One example is represented by SLC2A1 (GLUT-1) mutations, which can 
produce isolated PED (previously assigned the DYT18 number) 16, PED with inter-ictal 
spasticity (previously assigned the DYT9 number)17 as well as a number of other 
different phenotypes.    
 
3. Disorders presenting with paroxysmal dyskinesias  
3.1 PRRT2 
In 2011 Chen et al. first reported PRRT2 mutations as the genetic cause of PKD in 
eight families with PKD18, opening the way to the identification of PRRT2 mutation in 
several clinical syndromes previously associated with PKD such as the so-called ICCA 
syndrome (i.e., infantile convulsions with choreoathetosis) and BFIS syndrome (i.e., 
benign familial infantile seizures)19. Currently, PRRT2 is the major gene accounting for 
PKD, with a frequency ranging from about 40% to over 90%, depending on case 
ascertainment14,19,S1,S2. Onset of paroxysmal dyskinesias is in childhood, very rarely 
later than 18 years of age. In patients with ICCA, paroxysmal dyskinesias start after the 
onset of epilepsy (that develops within the first two years of life), usually after age 5, 
although some patients might exhibit epileptic seizures at a later age9,14,19.  
Virtually all PRRT2 cases have a clear kinesigenic trigger, although in up to 40-50% of 
cases anxiety, stress, startle or prolonged exercise can also induce attacks and very 
rarely (about 1-2% of patients) there are no kinesigenic triggers14. The episodes are 
very brief, usually lasting less than 1 minute, feature both chorea and dystonia, and 
tend to generalize14,19,S1,S2. About half of the patients experience a sensory aura at the 
initial site of the attacks that patients can use to predict attacks14. Often patients have 
hundreds of episodes per day, although the frequency of attacks usually decreases with 
advancing age after puberty and the syndrome can completely remit regardless of any 
treatments14,19,S1,S2.  Carbamazepine (CBZ) is the first line treatment option, being very 
effective at low doses (50-600 md/day) 14,19,S1-S4. A dramatic reduction in attacks is 
usually observed and this has been in fact suggested to be typical for patients with 
PRRT2 mutation as compared to similar cases of PKD and without such genetic 
defectS3,S4.  
It is however now clear that PRRT2 mutations can induce additional phenotypes 
including episodic ataxia and migraine, often of the hemiplegic subtype5,19,S5. As such, 
these features, whenever present in a single subject or in the family, make the presence 
of PRRT2 mutations likely.  
Interestingly, PRRT2 mutations have been recently identified in 2 out of 11 patients 
(18.2%) with PHD20, which supports the inclusion of PHD among the PxD. Moreover, 
PRRT2 mutations have been further associated with a phenotype reminiscent of benign 
paroxysmal torticollis of infancy (BTPI)21 and, in the case of biallelic mutations, with a 
complex phenotype including neurodevelopmental delay22. Complex phenotypes 
including PKD along with developmental delays, intellectual disability and language 
abnormalities, minor dysmorphic facial features, and/or autism spectrum disorder 
should also raise the suspicion of 16p11.2 (micro)deletions23,S6. In such rare cases, 
conventional genetic testing for PRRT2 mutations might be uninformative and 
microarray-based comparative genomic hybridization has to be performedS6. Table 1 
summarizes the clinical features of PRRT2 mutation as well as of the main genetic 
conditions producing PxD.  
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 Table 1. Characteristics of mutations mainly associated with paroxysmal dyskinesias  
AD: Autosomal Dominant; AR: Autosomal Recessive; PKD: Paroxysmal Kinesigenic Dyskinesias; 
PNKD: Paroxysmal Non-Kinesigenic Dyskinesias; PED: Paroxysmal Exercise-induced Dyskinesias; 
PND: Paroxysmal Nocturnal Dyskinesias; BPTI: Benign Paroxysmal Torticollis of Infancy; EA2: 




In 2004, MR-1 mutations were for the first time discovered in 2 unrelated families with 
PNKD24. Onset of the attacks is usually in the first decade5,18,24,S7. There is always a 
dominant family history for similar attacks, no sporadic cases having been reported 
thus far14. At the phenomenological level, attacks encompass both dystonic and 


















































































































be seldom complicated by dysarthria, dysphagia, oculogyric crises, inability to move, 
and/or pain and might also be fatal14,S9. The duration of the attacks is variable but often 
last for a few hours5,14,24,S7,S8. Although several non-kinesigenic triggers (i.e., stress, 
tiredness, sustained exercise) can be present, in patients with MR-1 mutations attacks 
are characteristically brought on by coffee and/or alcohol intake5,14,24,S7,S8 as compared 
to patients with PNKD but without mutations in this geneS7. MR-1 carriers do not have 
associated clinical features, with the exception of migraine in a few cases5, and the 
inter-ictal examination is always normal. Clonazepam is the first-line pharmacological 
option when lifestyle modifications (i.e., avoiding coffee and alcohol) are not 
efficacious14. Regardless of any treatment, there is a tendency for the attacks to reduce 
or remit in adulthood5,14,S7. Rarely, MR-1 mutations can manifest with very brief 
attacks trigger by sudden movements, therefore resembling classic PKDS10. 
3.3 SLC2A1  
Mutations in SLC2A1 encoding the glucose transporter type 1 (GLUT1) have been 
discovered to cause a spectrum of neurological phenotypes, including PED5,9,14-16. The 
latter is characterized by attacks of chorea and dystonia affecting mainly the lower 
limbs that are typically triggered by sustained exercise5,9,14-16,25. There is some 
phenotype-genotype correlation, with splice site, nonsense, insertions or deletions 
leading to loss of function SLC2A1 mutations being associated with younger age at 
onset and a more severe clinical phenotype of GLUT1 deficiency syndrome, including 
epilepsy, hypotonia, spasticity, ataxia, and developmental delay 14,25. This compares 
with missense SLC2A1 mutations, which more commonly present with PED in older 
patientsS11, the age at onset ranging from 1 to 50 years of age. As such, depending on 
the specific underlying genetic defect, PED can manifest as an isolated syndrome 
(about one-third of SLC2A1 cases) or be associated with other neurological 
disorders25,S11. Most cases with PED are de-novo, whereas only 10% have a positive 
family history15,16. Although autosomal recessive transmission has been described in 
rare cases of GLUT1 deficiency syndromeS12, this has not been reported in patients 
with PED. It is important to remark that while PED is the most common type of PxD 
reported in SLC2A1 cases, other non-kinesigenic triggers have also been described14 
and patients can manifest other episodic neurological disorders including episodic 
ataxia5,S13.  
PxD in the context of SLC2A1 cases have a positive but partial response to a ketogenic 
diet26, which should be pursued to treat the underlying neuroglycopenia. 
3.4 KNCMA1 
Mutations in KNCMA1, which encodes for a subunit of a calcium-activated potassium 
channel, have been reported in 2005 to cause a syndrome of PNKD and epilepsy27. 
Clinically, the PxD borne resemblance with the non-kinesigenic variant and alcohol 
was noted as a possible (but not constant) trigger27. Two additional PNKD patients with 
KCNMA1 mutations have been subsequently reported to lack epilepsy, but they 
presented with neurodevelopmental delayS14. As such, at variance from MR-1 patients, 
KCNMA1 mutations cause PNKD associated with either epilepsy or 
neurodevelopmental delay. PNKD in KNCMA1 carriers variably respond to 
antiepileptic drugs27,S14. 
3.5 ECHS1 
ECHS1 encodes for the short-chain enoyl-CoA hydratase protein, mutations of which 
have been reported as a cause of early-onset Leigh syndrome (or a Leigh-like syndrome 
with atypical, often milder form with later onset)S15. ECHS1 mutations have been 
further associated with PxD, which can be either isolated or combined with a number 
of features suggestive of a mitochondrial disease28–30,S15. Thus, ECHS1 mutations have 
been associated with intermittent episodes of long-duration (30-50 min) opisthotonus 
with no identifiable triggerS15, but also with episodes of dystonia clearly induced by 
sustained exercise29,30. Although a previous report has labelled the latter episodes as 
“kinesigenic” 28, a careful analysis of the original case description reveals that the 
attacks were actually triggered by “physical strain”28. Two more recent reports have 
confirmed that PxD due to ECHS1 mutations are more likely to be in the form of PED, 
with or without normal inter-ictal neurological examination29,30.  
It is worthy of note that all patients described so far have pallidal hyperintensity on T2-
MRI sequences (despite being very mild in one patient with isolated PED29), 
suggesting this might be a clue to suspect ECHS1 mutations.  A possible benefit with 
ketogenic diet or a mitochondrial cocktail including thiamine, riboflavin, carnitine, 
coenzyme Q-10, vitamin B6 and vitamin C has been reported in PxD28,30.  
3.6 Pyruvate dehydrogenase deficiency: PDHA1, PDHX and DLAT 
The mitochondrial pyruvate dehydrogenase complex (PDC) catalyzes the rate-limiting 
step in the aerobic glucose oxidation and comprises multiple copies of three subunits: 
pyruvate dehydrogenase (E1, encoded by the PDHA1 gene), dihydrolipoamide 
transacetylase (E2, encoded by the DLAT gene) and dihydrolipoamide dehydrogenase 
(E3), as well as an E3 binding protein (also known as component X and encoded by the 
PDHX gene)S16. Deficits in either subunit have been reported to cause PxD usually, but 
not always, embedded in complex neurologic pictures31,32,S17,S18.  
Mutations in the PDHA1 gene are typically associated with a wide range of clinical 
presentationsS16,S17. Most patients have severe, often lethal early encephalopathy with 
lactic acidosis. Some cases have more chronic or subacute neurodegenerative disorders 
ranging from Leigh syndrome, episodes of ataxia or recurrent acute flaccid paralysis 
S16,S17. Interestingly, a subset of patients manifest paroxysmal dystonia, which can be 
either isolated or combined with the aforementioned phenotypes or other clinical 
signs/symptoms including hypotonia, epilepsy and neurodevelopmental delayS16,S17. 
The paroxysmal dystonia might be brought on by prolonged exercise, thus meeting the 
criteria for PED, or without any clear trigger, thus falling into the PNKD 
category31,32,S17,S18. Attacks are sometimes reported to be hemi-dystonic. Similar attacks 
have been reported in patients with PDHX and DLAT mutations32,S16,S18 acknowledging 
that the latter two conditions are far less common than PDHA1 mutations.  
Raised (serum or CSF) lactate and/or pyruvate levels along with pallidal hyperintensity 
suggesting striatal necrosis are important clues to suspect PDC deficiency mutationsS16-
S18, but it is important to recognize that these might be lacking and, therefore, this 
condition should be considered in the differential diagnosis of isolated PED/PNKD 
even in the absence of any detectable biochemical or imaging abnormality, as it is a 
treatable condition that responds to thiamine supplementationS19. In other cases, 
beneficial outcomes have been also reported with a ketogenic dietS17, which supports 
energy failure as the main pathophysiological mechanism for the PxD occurring in the 
context of PDC deficiency.  
3.7 GCH1 
GCH1 codes for the GTP cyclohydrolase I, a rate limiting enzyme in the synthesis of 
tetrahydrobiopterin from GTP, mutations of which account for about 50% of dopa-
responsive dystonias.  A few patients with GCH1 mutations have been described with a 
phenotype consistent with PED. In 2010, Dale and colleagues described a family with 
two affected members with isolated PED33. Attack duration was about 5 minutes and 
they never occurred at rest or during movement initiation33. Moreover, Erro et al. found 
2 GCH1 carriers in a series of 16 patients with PED (12.5%)34. The phenomenology 
was that of dystonia and attacks were localized to the lower limbs34. As expected, 
patients had a dramatic benefit upon levodopa supplementation34.  
3.8 SCN8A  
Recently mutations in SCN8A, which encodes for sodium voltage-gated channel alpha 
subunit 8, have been suggested to be an alternative cause of the ICCA syndrome (i.e., 
PKD and infantile convulsions) in one recent report35. However, this proposal has been 
subsequently questionedS20 based on the evidence that, in one affected case, a “PKD” 
spell was recorded by video-EEG and a cortical signal was documented, suggesting 
that such attacks might in fact be epileptic in nature. Therefore, it is unclear whether 
mutations in this gene truly cause PKD or not. However, it has to be acknowledged that 
in other reports SCN8A mutations have been associated with episodic dystonia, 
although the term paroxysmal dyskinesia was not explicitly used36. As such, it is worth 
considering this condition in the differential diagnosis of PxD, especially when 
associated with epileptic seizures, particularly those refractory to antiepileptic therapy, 
and/or with neurodevelopmental delay36. 
3.9 ADCY5 
Mutations in ADCY5, which encodes for the adenylate cyclase 5, have been reported to 
cause a spectrum of (non-paroxysmal) movement disorders ranging from dystonia to 
chorea, sometimes associated with axial hypotonia and PxD37-39. PxD do not always fit 
clearly within previously identified PxD categories and might be painful, a point of 
difference from PxD due to other genetic causes of PxD37,39. Moreover, ADCY5-PxD 
may manifest, even within the same patient, as multiple sub-types, including PKD and 
PNKD37,39. Of note, also at variance with other genetic disorders that can produce PxD, 
ADCY5 carriers characteristically develop PxD during sleep39. Night-time dyskinesias 
(along with non-paroxysmal movement disorders) are therefore a clue to suspect 
ADCY5 mutations. Interestingly, Westenberger and colleagues have recently reported 
two unrelated ADCY5 patients with attacks reminiscent of Alternating Hemiplegia of 
Childhood (AHC; see below) in the context of a more complex neurological picture 
including dysarthria, hypotonia and non-paroxysmal choreo-dystonia40. Partial benefit 
has been reported with both tetrabenazineS21 and deep brain stimulation (DBS)S22.   
3.10 ATP1A3 
ATP1A3 mutations cause different clinical syndromes including AHC, Rapid-onset 
Dystonia Parkinsonism and Cerebellar Ataxia with Pes cavus and Optic neuropathy, 
although there is increasing evidence of overlapping phenotypes41,42,S23,S24. In the 
context of this review, we will only cover AHC. It is a largely sporadic disorder with 
onset within the first 18 months, by definition41,42. Despite its name, the highly 
distinguish feature of AHC is occurrence of frequent episodes of either hemi-dystonia 
or hemiplegia, which can manifest together with other paroxysmal neurological signs 
including nystagmus, anarthria, dysphagia, and seizures41,42,S24. Duration of attacks 
ranges from a few minutes to several days, and episodes occur from repeatedly within a 
day to several times a month41,42,S24. Attacks are almost invariably induced by 
emotional stressors, such as excitement or less frequently by physical stressors, 
including hypo- or hyperthermia, respiratory tract infections, and bright light41,42,S24. 
Characteristically, there is a rostrocaudal gradient in the hemiplegic/hemi-dystonic 
episodes (face/neck>arm>leg) 41,42,S24, which can aid the differentiation from other 
types of hemi-dystonic attacks.  Hemiplegic and hemi-dystonic episodes typically shift 
from one side of the body to the other and typically disappear falling asleep41,42,S24. 
Almost invariably the hemi-dystonic attacks are combined with other (inter-ictal) 
features such as developmental impairment, walking difficulties/ataxia, muscular 
hypotonia, dysarthria and choreoathetosis. The mainstay of treatment is flunarizine (10-
20 mg/day) as a prophylactic drug along with avoiding trigger situations41,42,S24. 
Patients should be encouraged to sleep when attacks begin, using fast-acting 
benzodiazepines if necessary.  
3.11 CACNA1A 
Mutations in the CACNA1A gene, which encodes for the calcium voltage-gated channel 
subunit alpha1 A, are associated with a number of phenotypes including SCA6, 
episodic ataxia type 2 as well as familial hemiplegic migraineS25. In a minority of cases, 
CACNA1A mutations have been suggested to account for some cases of paroxysmal 
benign torticollis of infancy (BPTI)43,44. It is characterized by episodes of head tilt with 
onset within the first 18 months of life that usually resolve by age 543,44. The attack 
duration ranges from 10 minutes to several days and are frequently accompanied 
vomiting, pallor, and ataxia43,44. BPTI usually resolves after infancy, but can be 
replaced by paroxysmal vertigo and/or migraine43,44.  The co-occurrence of episodic 
ataxia, hemiplegic migraine and paroxysmal tonic upgaze in a single subject or in the 
family make mutations in this gene more likely45. This condition is self-limiting and 
usually no treatment is required.  
3.12 SLC16A2 
SLC16A2 encodes for the monocarboxylate transporter type 8 (MCT8), which is 
required for trans-membrane uptake of free triiodothyronine (fT3) from blood into 
neurons. MCT8 deficiency results in a complex, X-linked disorder (also known as 
Allan-Herndon-Dudley syndrome) characterized by proximal hypotonia with poor head 
control, generalized muscular hypotrophy, microcephaly and marked developmental 
delay46.  
The disorder is progressive and spasticity, ataxia, and severe dysarthria complicate the 
clinical phenotype. In a subset of patients, a specific sort of PKD is observed46,47. 
Attacks are in fact classically triggered by passive movements such as changing of their 
clothes or nappies or by lifting the children from one place to another46,47. However, 
attacks can also be triggered by excitement, happiness or crying46,47. Attacks are brief, 
lasting seconds to few minutes, and are dystonic in nature46,47. The hallmark of MCT8 
deficiency is raised serum concentration of fT346.  
3.13 Other causes of paroxysmal dyskinesias  
Table 2 lists the conditions that have been associated with PxD or similar episodes of 
choreo-dystonia13,48,S26-S55. These include a variety of acquired, immunological and 
neurodegenerative causes that were formerly ascribed to secondary PxD13,48. For this 
reason, we have also included here brain calcification, by virtue of the fact that a 
lesional mechanism is assumed in such casesS35,S36. However, two PxD families have 
been recently reported on, in whom genetic analysis revealed novel mutations in 
SLC20A2 and PDGFB genes, respectivelyS48,S49. The fact that all affected members 
shared the phenotype of isolated PxD with normal inter-ictal examination S48,S49might 
support the idea that PxD are intrinsically associated with these mutations rather than 
being merely secondary to basal ganglia calcification, as assumed in earlier reports of 
the pre-genetic eraS49. This, however, remains speculative, but it further exemplifies the 
ambiguity regarding the concept of primary and secondary PxD.  
In general, PxD due to acquired, immunological or neurodegenerative causes, present 
usually at a later age compared to the main genetic forms reviewed above and manifest 
with additional signs or symptoms that will easily drive the diagnostic work-up and 
lead to the correct diagnosis and appropriate management in most cases.  
Recently, DEPDC5S10 and CHRNA449 mutations have been associated with the 
syndrome of PKD plus epilepsy in single families. However, these two genes are also a 
cause of ADNFLE50 and it remains to be seen whether these episodes of paroxysmal 
dystonia are epileptic in nature or not. Moreover, these results require replication 
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Table 2. Different aetiologies associated with episodic movement disorders 
resembling paroxysmal dyskinesias  
 
4. Proposed criteria for case-definition and diagnostic strategy 
Paroxysmal dyskinesias represent clinical syndromes where the disorder of movement 
is intermittent in nature (and thus does not encompass exacerbation of existing 
abnormalities). The intermittent character of the disorder means it is not continuous or 
steady, but should not be used to refer to disorders that wax-and-wane over a period of 
time such as tics.  
As to the phenomenology, the clinical spectrum ranges from dystonia to chorea, with 
ballism being possible but does not encompass tremor or myoclonus. Such a 
clarification automatically excludes stimulus-sensitive myoclonus or startle syndromes 
from this category. Moreover, excluded from this definition are those phenomena that 
are clearly drug-induced (i.e., acute dystonic reaction or levodopa-induced dyskinesias 
in the context of PD, for instance). 
Using this definition, the first step for the differential diagnosis is to decide whether the 
clinical abnormality is in fact a PxD or not. Epilepsy, tonic spasms, tetany, 
neuromyotonia, periodic paralyses, and episodic ataxias, all of which can produce 
intermittent disordered movements, need to be excluded clinically and/or by ancillary 
investigations whenever appropriate. Moreover, psychogenic/functional causes have to 
be ruled out. While some authors have suggested that the diagnosis of 
psychogenic/functional paroxysmal movement disorders is fundamentally one of 
exclusion, we would rather support alternative claims that the diagnosis should be 
based on the presence of positive signs: These include profound within-subject 
phenomenological variability with marked increases in attack frequency and severity 
during examination, highly variable attack duration, presence of several and non-
specific triggers, frequent alteration of responsiveness during attacks, medically 
unexplained somatic or neurological symptoms and, finally, atypical response to 
medications51,52. These clues will make a positive diagnosis of psychogenic/functional 
movement disorders likely, without the need for additional investigations in most, if not 
all, cases. 
Once the clinical syndrome of PxD is established, the second step is to fully 
characterize the attacks in terms of trigger and duration, further exploring the presence 
of family history and additional clinical features (by history or on examination) and to 
set the identified clinical syndrome in the context of age at onset. A clinical syndrome 
with onset in childhood, which is characterized by attacks with specific triggers and 
duration, is most likely to be genetic in nature. The definition of the trigger(s), duration, 
and body distribution of the attacks, as well as the presence of suggestive associated 
clinical features and the pattern of inheritance should help the clinician to drive the 
genetic analysis  (figure 1). Most of these disorders account for those forms that were 
formerly considered primary PxD and include PKD, PNKD and PED. While 
supporting the trigger-based approach as very useful, we further suggest some 
modifications and clarifications.  
For instance, the term non-kinesigenic does not carry any useful information rather 
than specifying that the trigger is not kinesigenic. It reflects the absence, rather than the 
presence, of a clinical feature with the obvious implication that, with one notable 
exception, the majority of non-kinesigenic triggers are non-specific and are shared 
across different PxD subtypes, being therefore not predictive of the underlying genetic 
defect. The exception is represented by alcohol/caffeine in the case of MR-1 mutations. 
The presence of this trigger is highly specific of MR-1 mutations, being present in 
about 95% of carriers. We therefore advocate considering alcohol/caffeine-sensitivity 
as a distinctive trigger for PxD rather than relegating it within the (unspecific) 
subgroup of non-kinesigenic triggers (figure 1). The vagueness of the non-kinesigenic 
category further justifies the fact that, in some instances, other clinical features such as 
the body distribution of the attacks might prevail in the definition of the paroxysmal 
movement disorders. This is the case of dystonic and hemiplegic attacks alternating 
from one body side to the other (AHC) or episodic attacks of neck dystonia (BPTI).      
Moreover, we support the concept of PxD occurring during sleep as a further trigger-
based subtype. Although sleep is not strictly a trigger, it can be considered equivalent 
to other triggers since they all give an answer to the question of when PxD occur (i.e., 
after sudden movements, after alcohol/caffeine ingestion, during sleep, etc.).  
At variance with former classifications of PxD, we discard the criterion of normal inter-
ictal examination. As such, all the aforementioned trigger-based subtypes can be 
isolated or combined with additional features. This reiterates a previous suggestion 
proposing the stratification of PxD into “pure” and “complicated” forms53, based on the 
absence or presence of additional inter-ictal neurological signs, respectively. We also 
advocate this approach for two main reasons. Firstly, there is evidence of clinical 
heterogeneity for single gene mutations. For instance, PRRT2 and SLC2A1 mutations 
can produce either isolated or combined PxD. Secondly, we believe the syndromic 
approach will facilitate the differential diagnosis (figure 1). For instance, the presence 
of epilepsy in a patient with “classic” PNKD will make the presence of MR-1 mutations 
very unlikely. Such a syndromic approach would also prioritize some investigations 
over others. This might be the case for PED in which CSF examination for glucose, 
pterin pathway components, pyruvate and lactate would provide more information than 
imaging. 
Whenever the attacks lack specific and consistent triggers, have variable duration, and 
when the onset is in adulthood,  “symptomatic” causes (table 2) need to be excluded, 
especially in the absence of family history. Given the huge variability of symptomatic 
PxD forms in their clinical presentation, even within the single subject, it is hard 
identify any phenotypic patterns suggestive of the underlying aetiology. In general, 
certain findings including painful attacks, fluctuating levels of consciousness, and 
dysautonomic crises that are not classically seen in the genetic conditions reviewed 
here, should prompt the clinician to rule out acquired causes. In such cases, an initial 
diagnostic work up including metabolic and electrolyte panels, investigation for 
autoimmune disorders, and brain imaging will allow a definitive diagnosis to be 
determined in most cases.  
 
5. Conclusions  
In recent years, great advances have led to a better understanding of the broad spectrum 
of genetic conditions underlying the PxD. This has increasingly challenged the former 
phenomenological classification as well as the idea that any specific phenotypes were 
associated to single gene mutations. Such an argument reiterates previous proposals14 
that classification of PxD should follow a two-pronged method, according to which 
both the clinical phenotype and the specific genetic mutation should be stated (PRRT2-
PKD for example). 
It is worth specifying that our proposal does not represent a classification scheme, but 
reflects an algorithmic approach to help clinicians in the differential diagnosis. First, it 
gives clarity to the definition of PxD. Second, it has the merit of encompassing an 
increasing number of recently identified conditions with PxD as a feature that would 
escape the current classification. On the other hand, the phenotypic and genetic 
heterogeneity of PxD highlighted here might render the test of candidate genes, based 
on a specific clinical syndrome, unsuccessful. In this context, it might be argued that 
next-generation sequencing approaches would better apply to the need of a rapid 
comprehensive genetic screening54. This would further reduce costs in comparison to 
single gene testing55. 
Of course there will be cases where no definitive cause for PxD can be found and 
treatment is to be pursued empirically. These can be labelled as idiopathic forms while 
awaiting for further elucidation of genetic or other causes. In turn, our proposal will 
require updating as soon as novel evidence is available.  
 
Figure caption 
Figure 1. Suggested genetic mutations that should be tested for according to clinical 
presentations 
^ = Mimics include epilepsy, tonic spasms, tetany, neuromyotonia, periodic paralyses, 
and episodic ataxias; #= these might include stress, anxiety, fatigue, fasting, startle and 
sleep deprivation; § = by history or on examination; - = none/negative; + = present; AD 
= Autosomal Dominant; E=Epilepsy; M=Migraine; EA= Episodic Ataxia; MR= Mental 
Retardation; HP=Hemiplegia; A=Ataxia; Au=Autonomic dysfunction; S=Spasticity; 
MD= non-paroxysmal movement disorders; *including 16p11.2 deletion; ≅ = might 




We thank Dr. K. Bertram for having edited the text. 
 
References 
1. Bhatia KP. Paroxysmal dyskinesias. Mov Disord. 2011;26:1157-65 
2. Collins English Dictionary. HarperCollins Publishers Ltd; [12th edition] 2014. 
3. Mosby's Medical Dictionary. Elsevier; [9th edition] 2009 
4. Collins Dictionary of Medicine. Robert M. Youngson. Collins; 2004. 
5. Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity 
of paroxysmal dyskinesias. Brain 2015;138:3567–80. 
6. Groffen AJ, Klapwijk T, van Rootselaar AF, Groen JL, Tijssen MA. Tjssen 
overlap Genetic and phenotypic heterogeneity in sporadic and familial forms of 
paroxysmal dyskinesia. J Neurol. 2013;260:93-9 
7. Wang K, Zhao X, Du Y, He F, Peng G, Luo B. Phenotypic overlap among 
paroxysmal dyskinesia subtypes: Lesson from a family with PRRT2 gene mutation. 
Brain Dev 2013;35:664–66. 
8. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett 
M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology 
and classification of dystonia: a consensus update. Mov Disord. 2013;28:863-73. 
9. Erro R, Bhatia KP, Espay AJ, Striano P. The epileptic and nonepileptic 
spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and 
transportopathies. Mov Disord. 2017;32:310–18. 
10.  Mount L, Reback S. Familial paroxysmal choreoathetosis. Arch Neurol 
1940;44:841–47. 
11. Kertesz A. Paroxysmal kinesigenic choreoathetosis: an entity within the 
paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. 
Neurology 1967;17:680–90. 
12.  Lance JW. Familial paroxysmal dystonic choreoathetosis and its 
differentiation from related syndromes. Ann Neurol 1977;2:285–93.  
13.  Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and 
classification. Ann Neurol 1995;38:571-579 
14. Erro R, Sheerin UM, Bhatia KP. Paroxysmal dyskinesias revisited: a review of 500 
genetically proven cases and a new classification. Mov Disord. 2014;29(9):1108-16 
15. Webster’s New World Medical Dictionary. Hoboken, NJ: Wiley; 2008. 
16.  Weber YG, Storch A, Wuttke TV, et al. GLUT1 mutations are a cause of 
paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. 
J Clin Invest 2008;118:2157–68. 
17.  Weber YG, Kamm C, Suls A, et al. Paroxysmal choreoathetosis/spasticity 
(DYT9) is caused by a GLUT1 defect. Neurology. 2011;77:959–64 
18.  Chen WJ, Lin Y, Xiong ZQ, et al. Exome sequencing identifies truncating 
mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet. 
2011;43:1252–55.  
19. Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum 
of PRRT2-associated paroxysmal diseases. Brain. 2015;138:3476–95 
20. Liu XR, Huang D, Wang J, Wang YF, Sun H, Tang B, Li W, Lai JX, He N, Wu M, 
Su T, Meng H, Shi YW, Li BM, Tang BS, Liao WP. Paroxysmal hypnogenic 
dyskinesia is associated with mutations in the PRRT2 gene. Neurol Genet. 
2016;2(2):e66. 
21.  Dale RC, Gardiner A, Antony J, Houlden H. Familial PRRT2 mutation with 
heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic 
migraine. Dev. Med. Child Neurol. 2012; 54:958–60. 
22.  Delcourt M, Riant F, Mancini J, et al. Severe phenotypic spectrum of biallelic 
mutations in PRRT2 gene. J Neurol Neurosurg Psychiatry. 2015;86:782–5 
23. Weber A, Köhler A, Hahn A, Neubauer B, Müller U. Benign infantile 
convulsions (IC) and subsequent paroxysmal kinesigenic dyskinesia (PKD) in a patient 
with 16p11.2 microdeletion syndrome. Neurogenetics. 2013;14:251–3 
24.  Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene 
mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol 2004;61:1025–29. 
25. Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency 
syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 
2010;133:655–70.  
26. Leen WG, Mewasingh L, Verbeek MM, Kamsteeg EJ, van de Warrenburg BP, 
Willemsen MA. Movement disorders in GLUT1 deficiency syndrome respond to the 
modified Atkins diet. Mov Disord. 2013;28:1439-42 
27.  Du W, Bautista JF, Yang H, Diez-Sampedro A, You SA, Wang L, Kotagal P, 
Lüders HO, Shi J, Cui J, Richerson GB, Wang QK. Calcium-sensitive potassium 
channelopathy in human epilepsy and paroxysmal movement disorder. Nat Genet. 
2005;37:733-8.  
28.  Korenke GC, Nuoffer J-M, Alhaddad B, Mayr H, Prokisch H, Haack TB. 
Paroxysmal Dyskinesia in ECHS1 Defect with Globus Pallidus Lesions. 
Neuropediatrics 2016; 47:PS01-10. DOI: 10.1055/s-0036-1583605 
29.  Olgiati S, Skorvanek M, Quadri M, Minneboo M, Graafland J, Breedveld GJ, 
et al. Paroxysmal exercise-induced dystonia within the phenotypic spectrum of ECHS1 
deficiency. Mov Disord. 2016;31:1041-8 
30.  Mahajan A, Constantinou J, Sidiropoulos C. ECHS1 deficiency-associated 
paroxysmal exercise-induced dyskinesias: case presentation and initial benefit of 
intervention. J Neurol. 2017;264:185-187 
31.  McWilliam CA, Ridout CK, Brown RM, McWilliam RC, Tolmie J, Brown 
GK. Pyruvate dehydrogenase E2 deficiency: a potentially treatable cause of episodic 
dystonia. Eur J Paediatr Neurol. 2010;14:349–53 
32. Friedman J, Feigenbaum A, Chuang N, Silhavy J, Gleeson JG. Pyruvate 
dehydrogenase complex-E2 deficiency causes paroxysmal exercise-induced dyskinesia. 
Neurology. 2017;89:2297-2298.  
33. Dale RC, Melchers A, Fung VS, Grattan-Smith P, Houlden H, Earl J. Familial 
paroxysmal exercise-induced dystonia: atypical presentation of autosomal dominant 
GTP-cyclohydrolase 1 deficiency. Dev Med Child Neurol. 2010;52:583-6 
34.  Erro R, Stamelou M, Ganos C, Skorvanek M, Han V, Batla A, Bhatia KP. 
The Clinical Syndrome of Paroxysmal Exercise-Induced Dystonia: Diagnostic 
Outcomes and an Algorithm. Mov Disord Clin Pract. 2014;1:57-61 
35.  Gardella E, Becker F, Møller RS, Schubert J, Lemke JR, Larsen LH, et al. 
Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. 
Ann Neurol. 2016;79:428-36 
36.  Larsen J, Carvill GL, Gardella E, et al.; EuroEPINOMICS RES Consortium 
CRP. The phenotypic spectrum of SCN8A encephalopathy. Neurology 201;84:480–9 
37. Chen DH, Méneret A, Friedman JR, et al. ADCY5-related dyskinesia: Broader 
spectrum and genotype-phenotype correlations. Neurology. 2015;85:2026–35 
38.  Mencacci NE, Erro R, Wiethoff S, et al. ADCY5 mutations are another cause 
of benign hereditary chorea. Neurology. 2015;85:80–8. 
39.  Friedman JR, Méneret A, Chen DH, et al. ADCY5 mutation carriers display 
pleiotropic paroxysmal day and nighttime dyskinesias. Mov Disord. 2016;31:147-8. 
40.  Westenberger A, Max C, Brüggemann N, Domingo A, Grütz K, Pawlack H, 
et al. Alternating Hemiplegia of Childhood as a New Presentation of Adenylate 
Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. J Pediatr. 
2017;181:306-308 
41.  Heinzen EL, Arzimanoglou A, Brashear A, et al.; ATP1A3 Working Group. 
Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 2014;13:503–
14. 
42. Rosewich H, Ohlenbusch A, Huppke P, et al. The expanding clinical and 
genetic spectrum of ATP1A3-related disorders. Neurology. 2014;82:945–55. 
43. Giffin NJ, Benton S, Goadsby PJ. Benign paroxysmal torticollis of infancy: 
four new cases and linkage to CACNA1A mutation. Dev. Med. Child Neurol. 2002;44: 
490–3 
44. Vila-Pueyo M, Gene GG, Flotats-Bastardes M et al. A loss-of-function 
CACNA1A mutation causing benign paroxysmal torticollis of infancy. Eur J Paediatr 
Neurol. 2014;18:430–3 
45. Shin M, Douglass LM, Milunsky JM, Rosman NP. The Genetics of Benign 
Paroxysmal Torticollis of Infancy: Is There an Association With Mutations in the 
CACNA1A Gene? J Child Neurol. 2016;31:1057–61 
46. Fuchs O, Pfarr N, Pohlenz J, Schmidt H. Elevated serum triiodothyronine and 
intellectual and motor disability with paroxysmal dyskinesia caused by a 
monocarboxylate transporter 8 gene mutation. Dev Med Child Neurol. 2009;51:240-4 
47.  Brockmann K, Dumitrescu AM, Best TT, Hanefeld F, Refetoff S. X-linked 
paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. J 
Neurol. 2005;252:663–6 
48. Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord. 
2002;17:726–34 
49. Jiang YL, Yuan F, Yang Y, Sun XL, Song L, Jiang W. CHRNA4 variant causes 
paroxysmal kinesigenic dyskinesia and genetic epilepsy with febrile seizures plus? 
Seizure. 2018 Feb 10;56:88-91  
50. Kurahashi H, Hirose S. Autosomal Dominant Nocturnal Frontal Lobe Epilepsy. In: 
Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, 
editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 
1993-2018. 2002 May 16 [updated 2018 Mar 15] 
51. Ganos C, Aguirregomozcorta M, Batla A, Stamelou M, Schwingenschuh P, 
Münchau A, et al. Psychogenic paroxysmal movement disorders--clinical features and 
diagnostic clues. Parkinsonism Relat Disord. 2014;20(1):41-6 
52. Erro R, Brigo F, Trinka E, Turri G, Edwards MJ, Tinazzi M. Psychogenic 
nonepileptic seizures and movement disorders: A comparative review. Neurol Clin 
Pract. 2016;6(2):138-149 
53. Brockmann K, Rosewich H. Genetics of paroxysmal dyskinesia. In: Schneider SA, 
Bras JMT (eds.): Movement Disorder Genetics. Springer 2015, pp 191-212 
54. Di Fonzo A, Monfrini E, Erro R. Genetics of Movement Disorders and the 
Practicing Clinician; Who and What to Test for? Curr Neurol Neurosci Rep. 
2018;18(7):37. 
55. van Egmond ME, Lugtenberg CHA, Brouwer OF, Contarino MF, Fung VSC, 
Heiner-Fokkema MR, et al. A post hoc study on gene panel analysis for the diagnosis 
of dystonia. Mov Disord. 2017;32(4):569–75. 
 
